The gross proceeds from the offering are expected to be approximately $5 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company. Pasithea intends to use ...

Sudden uncontrollable and inappropriate laughing or crying is a symptom of pseudobulbar affect (PBA), a neurological ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

In a first-of-a-kind collaboration, Target ALS, a foundation breaking down barriers to amyotrophic lateral sclerosis (ALS) ...

A tailored cocktail of genes can reprogram a subset of progenitors to no longer produce glial cells and instead develop into neurons involved in motor control.

A New Bedford man, Joseph Smith, admitted to stealing over $450,000 in disability benefits from a veteran with ALS and ...

Founded in 2009, the Luxembourg Centre for Systems Biomedicine (LCSB) is celebrating 15 years of contribution to biomedical research in Luxembourg and beyond. Focusing on neurodegenerative disorders ...

Spinogenix, the company behind the once-a-day pill that restored lost nerve cell connections in people with amyotrophic ...

PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has launched a study with ...

Two specific conditions are exempt from the 24-month waiting period: end-stage kidney disease and amyotrophic lateral sclerosis (ALS). Individuals with these diseases can qualify for Medicare no ...